• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 13, 2013

View Archived Issues

Lake 'Plasmid' Storm? Vical's Phase III Bust Not an Indicator

Vical Inc.'s stock-bashing Phase III failure against metastatic melanoma with Allovectin (velimogene aliplasmid) caused at least one analyst to question the plasmid DNA platform that is the subject of another late-stage program with Astellas Pharma Inc. in a separate indication, as well as independent efforts. Read More

Solid Signal in GBM, Celldex Expands ReACT GBM Study

Based on early evidence of efficacy in an initial cohort of 25 patients refractory to Avastin (bevacizumab, Roche AG unit Genentech Inc.), Celldex Therapeutics Inc. added an expansion cohort of approximately 75 patients to its Phase II ReACT study of rindopepimut in EGFRvIII (v3)-positive glioblastoma (GBM), seeking a better bead on the compound's potential activity in a refractory patient population. Read More

Sinopharm Building Biotech Research Center in China

SHANGHAI – The announcement that China's largest pharmaceutical company will build the country's largest biotechnology research center in Wuhan is cementing the reputation of the Chinese city as a global biotech center. China National Pharmaceutical Group Corp. (Sinopharm) plans to build the center at the Wuhan National Bioindustry Base, also known as Biolake, in the city of Wuhan in Hubei Province. Read More

Eisai: FDA Action Is Robbing Belviq of Exclusivity

The FDA jumped the gun on clocking the five-year exclusivity of Belviq from the date it granted approval – a move that would rob the obesity drug of nearly a year of exclusivity, Eisai Inc. claimed in a recent citizen petition that asks the agency to reset the clock. Read More

Matinas Biopharma Raises $15M for Omega-3 Therapeutic

Poised to file an investigational new drug application for its lipid drug MAT9001, Tarpon Springs, Fla.-based Matinas Biopharma Holdings Inc. raised $15 million in a private placement financing. Read More

Topotarget Investors Nervous About Belinostat NDA Delay

Investors in Topotarget A/S got a dose of the jitters on news that its development partner, Spectrum Pharmaceuticals Inc., will delay its new drug application (NDA) filing of Topotarget's belinostat to the fourth quarter, pushing into next year the payment dates for two badly needed milestones. Read More

MiR-192 is New Tool for Influenza Biocontainment

Creating more dangerous strains of flu viruses for research purposes is a double-edged sword. Researchers have developed a novel biocontainment strategy for such viruses. It consists of adding a gene that makes them a target for destruction in the human lung, but not the lungs of ferrets. Read More

Other News To Note

• Advanced Cell Technology Inc. (ACT), of Marlborough, Mass., filed preliminary proxy materials with the SEC in connection with its 2013 annual stockholders meeting proposing, among other matters, to increase the authorized shares of its common stock to 3.75 billion from 2.75 billion. Read More

Stock Movers

Read More

Clinic Roundup

• Immunomedics Inc., of Morris Plains, N.J., said that the three Phase I trials evaluating the company's antibody-drug conjugates (ADCs) in patients with diverse solid tumors have now advanced to Phase II trials. Read More

Pharma: Other News To Note

• Teva Pharmaceutical Industries Ltd., of Jerusalem, and Perrigo Co., of Allegan, Mich., launched a generic equivalent to Temodar (temozolamide). Teva has agreed to manufacture, market and distribute the product in the U.S. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • White puzzle pieces on blue background

    Highridge sells bone healing business to Avista

    BioWorld MedTech
    In the midst of June’s peak wedding season, Highridge Medical LLC called it splitsville – selling its bone healing division to Avista Healthcare Partners. The...
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe